ClinicalTrials.gg

Program

Clopidogrel

Also written as “clopidogrel”, “clopidogrel (SR25990C)” and “Clopidogrel (SR25990)”.

Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Acute Coronary Syndrome · Heart Defects, Congenital · Diabetes Mellitus, Type 2, led by 17 companies.

Furthest: phase 4, since Feb 23, 200655 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi250 open or runningphase 4since Feb 23, 2006Dec 20, 2002none ahead
Dr. Reddy's Laboratories40 open or runningphase 1since Jan 6, 2012Jan 6, 2012none ahead
AstraZeneca30 open or runningphase 1since Jun 4, 2010Jun 4, 2010none ahead
Bristol-Myers Squibb30 open or runningphase 1since Jul 8, 2009Jul 8, 2009none ahead
Eli Lilly30 open or runningphase 2since Jul 26, 2006Jul 26, 2006none ahead
Viatris30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Johnson & Johnson20 open or runningphase 2since Nov 13, 2014Nov 13, 2014none ahead
les-laboratoires-des-me-dicaments-ste-riles20 open or runningphase 4since Aug 25, 2011Aug 25, 2011none ahead
Merck20 open or runningphase 1since Nov 10, 2009Nov 10, 2009none ahead
accumetrics-inc10 open or runningno phasesince Mar 24, 2008Mar 24, 2008none ahead
Boston Scientific10 open or runningphase 4since May 1, 2012May 1, 2012none ahead
Cordis10 open or runningphase 4since Aug 6, 2009Aug 6, 2009none ahead
Hanmi Pharmaceutical10 open or runningphase 4since Apr 5, 2013Apr 5, 2013none ahead
laboratoires-teriak10 open or runningphase 4since Oct 14, 2017Oct 14, 2017none ahead
Novo Nordisk10 open or runningphase 1since May 16, 2012May 16, 2012none ahead
Otsuka10 open or runningphase 1since Sep 15, 2015Sep 15, 2015none ahead
Pharmtechnology10 open or runningphase 1since Jun 28, 2023Jun 28, 2023none ahead

Also a collaborator on its studies: Bayer and Daiichi Sankyo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 40 studies since Dec 20, 2002.

  1. Jan 9, 2012Phase 4 study in Cardiovascular Diseasesles-laboratoires-des-me-dicaments-ste-riles · NCT01509365 · 116 enrolled · Tunisia
  2. May 1, 2012Boston Scientific's first study: phase 4 study in Coronary Artery DiseaseNew to Boston ScientificBoston Scientific · NCT01589978 · 2,681 enrolled · United States
  3. May 16, 2012Novo Nordisk's first study: phase 1 study in HaemostasisNew to Novo NordiskNovo Nordisk · NCT01603342 · 18 enrolled · United States
  4. Jun 14, 20122 phase 1 studiesDr. Reddy's Laboratories · NCT01621763, NCT01621750
  5. Apr 5, 2013Hanmi Pharmaceutical's first study: phase 4 study in Coronary Artery DiseaseNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01830491 · 162 enrolled
  6. Jul 4, 2014Phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsAstraZeneca · NCT02185534 · 144 enrolled · Germany
  7. Nov 13, 2014Johnson & Johnson's first study: phase 2 study in Acute Coronary SyndromeNew to Johnson & JohnsonJohnson & Johnson · NCT02293395 · 3,037 enrolled · United States, Argentina, Australia and more
  8. Apr 2, 2015Phase 1 study in ThrombosisBristol-Myers Squibb · NCT02439190 · 42 enrolled · United Kingdom
  9. Sep 15, 2015Otsuka's first study: phase 1 study in HealthyNew to OtsukaOtsuka · NCT02554721 · 77 enrolled · Germany
  10. Oct 14, 2017laboratoires-teriak's first study: phase 4 study in Diabetes Mellitus, Type 2New to laboratoires-teriaklaboratoires-teriak · NCT03329261 · 167 enrolled · Tunisia
  11. Jan 30, 2018Phase 1 study in HealthyViatris · NCT03430661 · 77 enrolled · United States
  12. Apr 6, 2018Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT03496506 · 22 enrolled · Belgium
  13. Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
  14. Jun 28, 2023Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT05934799 · 60 enrolled · Russian Federation

TargetBeta

P2RY12 →read by rule
“Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule

Other programs on P2RY12

ProgramCompanyFurthest phaseStudies
TicagrelorruleAstraZenecaphase 447
selatogrelruleViatrisphase 311

Studies

All 55 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05934799Bioequivalence · Russian Federation1CompletedPharmtechnologyJul 23, 202360
NCT03698513Healthy Volunteers · United States1CompletedBristol-Myers SquibbFeb 19, 2019113
NCT03496506Healthy Subjects · Belgium1CompletedJohnson & JohnsonMay 10, 201822
NCT03430661Healthy · United States1CompletedViatrisMay 20, 201977
NCT03329261Diabetes Mellitus, Type 2 · Tunisia4Completedlaboratoires-teriakMar 24, 2019167
NCT02554721Healthy · Germany1CompletedOtsukaMar 30, 201877
NCT02439190Thrombosis · United Kingdom1CompletedBristol-Myers SquibbMar 201642
NCT02293395Acute Coronary Syndrome · United States, Argentina, Australia and more2CompletedJohnson & JohnsonOct 14, 20163,037
NCT02185534Bioequivalence, AUC, Cmax, Pharmacokinetics · Germany1CompletedAstraZenecaOct 2014144
NCT01830491Coronary Artery Disease4CompletedHanmi PharmaceuticalAug 2009162
NCT01621763Healthy · India1CompletedDr. Reddy's LaboratoriesSep 200868
NCT01621750Fasting · India1CompletedDr. Reddy's LaboratoriesSep 200868
NCT01603342Haemostasis · United States1CompletedNovo NordiskJan 200818
NCT01589978Coronary Artery Disease · United States4CompletedBoston ScientificAug 20142,681
NCT01512485Healthy · Canada1CompletedDr. Reddy's LaboratoriesOct 200651
NCT01509365Cardiovascular Diseases · Tunisia4Completedles-laboratoires-des-me-dicaments-ste-rilesFeb 2015116
NCT01506713Fasting · Canada1CompletedDr. Reddy's LaboratoriesSep 200653
NCT01431495Coronary Disease · Tunisia4Completedles-laboratoires-des-me-dicaments-ste-rilesJun 2011219
NCT01263093Depressive Disorder, Major · United States1CompletedEli LillyMar 201147
NCT01210339Cardiovascular Diseases · Sweden1CompletedAstraZenecaAug 201158
NCT01147588Healthy · United States1CompletedAstraZenecaMay 2011149
NCT01129427Healthy · United States1CompletedSanofiNov 200966
NCT01129414Healthy · United States1CompletedSanofiAug 200972
NCT01129388Healthy · United States1CompletedSanofiMay 200972
NCT01129375Healthy · United States1CompletedSanofiMay 200972
NCT01129271Healthy · United States, France1CompletedSanofiJun 200972
NCT01129063Healthy · France1CompletedSanofiMay 200932
NCT01123824Healthy · Germany1CompletedSanofiAug 200940
NCT01115738Acute Coronary Syndrome · India2CompletedEli LillyNov 2011282
NCT01108588Healthy Volunteers1CompletedMerckAug 201015
NCT01012219Hyperlipoproteinemia Type II1CompletedMerckMar 201036
NCT00954707Coronary Artery Disease · United States4UNKNOWNCordisJan 20122,509
NCT00935506Cardiovascular Diseases · United States1CompletedBristol-Myers SquibbOct 200915
NCT00862420Peripheral Arterial Disease · Japan3CompletedSanofiMay 2011431
NCT00833703Heart Defects, Congenital · United States, Brazil, France and more3CompletedSanofiJul 201049
NCT00821834Angina, Stable · Japan3CompletedSanofiAug 20101,003
NCT00814268Stroke · Korea, Republic of4CompletedSanofiMay 2012358
NCT00716924Thrombosis · Mexico3CompletedSanofiFeb 2006155
NCT00714961Acute Coronary Syndrome · United States, Argentina, Australia and more3CompletedSanofiJan 20053,491
NCT00650169Healthy · United States1CompletedViatrisJan 200547
NCT00648947Healthy · United States1CompletedViatrisDec 200446
NCT00648453Peripheral Arterial Disease · Hungary4CompletedSanofi39
NCT00645918Coronary Artery Disease · United States, Canada–Completedaccumetrics-incOct 20102,800
NCT00396877Heart Defects, Congenital · United States, Argentina, Belgium and more3CompletedSanofiFeb 2010906
NCT00386191Cerebral Infarction · Japan4CompletedSanofiDec 20081,110
NCT00360386Ischemia2CompletedSanofiFeb 2005110
NCT00357968Coronary Artery Disease · United States, France, Germany and more2CompletedEli LillyJun 2007201
NCT00335452Angina, Unstable · United States, Argentina, Australia and more3CompletedSanofiSep 200925,086
NCT00325390Platelet Aggregation Inhibitors · Japan3CompletedSanofi800
NCT00296803Metabolic Syndrome · United States4CompletedSanofi216
NCT00249873Atrial Fibrillation · United States, Argentina, Australia and more3CompletedSanofiMar 20097,554
NCT00243178Atrial Fibrillation · United States, Australia, Austria and more3TerminatedSanofiSep 20056,706
NCT00174759Arterial Occlusive Diseases · Australia, Austria, Belgium and more3CompletedSanofi1,460
NCT00115375Heart Defects, Congenital · United States, Belgium, Canada and more2CompletedSanofi92
NCT00050817Arteriosclerosis · United States, Argentina, Australia and more3CompletedSanofi15,603

How it is read

Names in the registry

  • “Clopidogrel”, 41 entries
  • “clopidogrel”, 11 entries
  • “clopidogrel (SR25990C)”, 4 entries
  • “Clopidogrel (SR25990)”, 3 entries
  • “clopidogrel (SR25990)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.